Itamar Medical - ADR Peer Comparison
$0.00
$--
(--%)
As on 30-Dec-2021EDT
Market cap
$507 Mln
Revenue (TTM)
$51 Mln
P/E Ratio
--
P/B Ratio
6.8
Div. Yield
0 %
Edit
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
507 | 12,753 | 12,153 | 10,906 | 9,948 |
Revenue ($ Mln) |
51 | 1,505 | 6,164 | 613 | 785 |
Net Profit ($ Mln) |
-21.19 | 160.59 | 625.00 | -188.05 | 41.54 |
Net Margin (%) |
-41.66 | 10.67 | 5.41 | -30.68 | 5.29 |
RoE (%) |
-26.53 | 10.86 | 11.84 | -28.10 | 1.97 |
Price to Earnings |
-- | 79.35 | 19.89 | -- | 251.81 |
Price-To-Book |
6.84 | 8.41 | 2.37 | 16.38 | 4.86 |
Income Statement ($ Mln)
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
50.88 | 560.41 | 4,560.00 | 224.96 | 366.26 |
|
Cost of Revenue
|
15.88 | 222.24 | 1,381.00 | 91.72 | 171.91 |
|
Gross Profit
|
28.71 | 338.18 | 3,179.00 | 133.24 | 194.36 |
|
Operating Expenses
|
61.08 | 377.12 | 2,884.00 | 256.79 | 113.07 |
|
Operating Profit (EBIT)
|
-18.18 | -38.94 | 295.00 | -123.55 | 81.29 |
|
Other Income
|
0.00 | -0.34 | -- | 2.38 | 1.53 |
|
Profit before Tax
|
-20.67 | -38.02 | 246.00 | -132.31 | 59.22 |
|
Provision for Tax
|
0.52 | -18.76 | 202.00 | -11.97 | -0.71 |
|
Profit after Tax (Net Income)
|
-21.19 | -19.26 | 448.00 | -120.35 | 59.93 |
|
Minority Interest
|
0.00 | -3.71 | -- | -- | -- |
|
Consolidated Profit
|
-21.19 | -15.70 | 448.00 | -120.35 | 59.93 |
Liabilities ($ Mln)
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
73.93 | 641.50 | 5,279.00 | 667.45 | 1,529.15 |
|
Minority Interest
|
0.00 | -3.71 | -- | -- | -- |
|
Non-Current Liabilities
|
6.63 | 79.26 | 4,045.00 | 288.35 | 54.78 |
|
Current Liabilities
|
21.78 | 105.93 | 1,688.00 | 49.70 | 318.96 |
|
Total Liabilities
|
64.14 | 822.98 | 11,012.00 | 1,005.50 | 1,902.89 |
Assets ($ Mln)
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
12.51 | 205.28 | 6,348.00 | 536.06 | 1,000.51 |
|
Current Assets
|
89.83 | 617.70 | 4,664.00 | 469.44 | 902.38 |
|
Total Assets
|
64.14 | 822.98 | 11,012.00 | 1,005.50 | 1,902.89 |
|
Total Debt*
|
10.85 | 77.28 | 3,690.00 | 272.00 | 275.42 |
|
Net Current Assets
|
68.05 | 511.77 | 2,976.00 | 419.74 | 583.43 |
Cashflow ($ Mln)
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-8.82 | -33.24 | 935.00 | -22.99 | 62.63 |
|
Cash Flow from Investing Activities
|
-32.28 | -104.15 | -606.00 | -205.06 | -201.39 |
|
Cash from Financing Activities
|
35.46 | 134.92 | 1,164.00 | 262.54 | 305.92 |
|
Net Cash Inflow / Outflow
|
-- | -2.47 | -- | 34.41 | 179.89 |
Ratios
Profitability Ratios
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-33.29 | -2.99 | 5.55 | -14.28 | 3.83 |
|
ROE (%)
|
-26.53 | -3.42 | 8.60 | -17.95 | 4.63 |
|
ROA (%)
|
-20.82 | -2.59 | 4.41 | -13.20 | 3.63 |
|
EBIT Margin (%)
|
-37.76 | -- | -- | -- | -- |
|
Net Margin (%)
|
-41.66 | -3.44 | 9.82 | -52.94 | 16.29 |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.03 | 0.02 | -0.11 | -0.05 | 0.36 |
|
EBIT Growth (%)
|
-128.66 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-135.52 | -139.74 | -25.33 | -880.26 | 179.88 |
|
EPS Growth (%)
|
-- | -1.39 | -0.26 | -8.51 | 1.69 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -340.37 | 82.87 | -28.17 | 175.95 |
|
Price / Book Value
|
-- | 10.22 | 7.03 | 5.08 | 6.90 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
3.99 | -244.40 | 42.28 | -38.98 | 102.65 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.12 | 0.70 | 0.41 | 0.18 |
|
Short term debt to equity ratio
|
0.08 | 0.01 | 0.06 | 0.00 | 0.16 |
|
Current Ratio
|
4.12 | 5.83 | 2.76 | 9.45 | 2.83 |
|
Quick Ratio
|
3.78 | 3.76 | 1.76 | 9.13 | 2.53 |
|
Interest Coverage
|
-12.13 | -2.24 | 6.93 | -8.37 | 5.88 |
Operating Efficiency Ratios
| Itamar Medical - ADR | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
27.12 | 20.45 | 19.98 | 16.03 | 19.49 |
|
Asset Turnover
|
0.50 | 0.75 | 0.45 | 0.25 | 0.22 |
|
Receivable days
|
83.40 | 71.86 | 79.82 | 60.46 | 57.37 |
|
Inventory Days
|
156.01 | 306.12 | 437.06 | 116.26 | 159.20 |
|
Payable days
|
95.53 | 24.01 | 242.27 | 20.21 | 30.07 |
|
Cash Conversion Cycle
|
143.88 | 353.97 | 274.61 | 156.50 | 186.50 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
